JPMorgan analyst Jessica Fye lowered the firm’s price target on Novocure (NVCR) to $23 from $25 and keeps a Neutral rating on the shares. The firm updated the company’s model to reflect increased long-term conservatism.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR: